CSE’s White Paper on Promoting Integrity in Scientific Journal Publications
CSE’s White Paper on Promoting Integrity in Scientific Journal Publications was first published in 2006 and the full document was updated in 2009 and again in 2012. Since May 2018, the paper is updated on a rolling basis as new sections are added and/or existing sections are updated to reflect new information or best practices. This updated method for amending the document will allow for more rapid dissemination of updates. E-mails from the CSE Marketing Committee as well as Commentaries in Science Editor will alert the membership to the updates.
2.0 ROLES AND RESPONSIBILITIES IN PUBLISHING
2.1 Editor Roles and Responsibilities *Updated July 2020
2.1.1 Editorial Freedom
2.1.3 Conflicts of Interest
2.1.4 Conflict of Interest Disclosure
2.1.5 Citation Manipulation
2.1.6 Editorial Board Participation
2.1.7 Supplements, Special Series, or Calls for Papers *New Sept. 2021
2.1.8 Timeliness of the Publication Process
2.1.9 Errata, Retractions, and Expressions of Concern
2.1.10 Addressing Authorship Disputes
2.1.11 Considering Appeals for Reconsideration of Rejected Manuscripts
2.1.12 Addressing Allegations or Findings of Misconduct (see section 3.0)
2.1.13 Preprint Servers*Updated February 2022
2.1.15 Resources and Case Studies
2.2 Authorship and Author Responsibilities *Updated June 2020
2.2.2 Other Authorship Issues
2.2.4 Order of Authors
2.2.5 Changes to the Author Byline
2.2.6 Author Responsibilities
2.2.8 Resources and Case Studies
2.3 Reviewer Roles and Responsibilities *Updated June 2020
2.3.1 Reviewer Selection
2.3.2 Ethical Responsibilities of Reviewers
2.3.3 Examples of Reviewer Impropriety
2.3.4 Using Anonymous Reviewers vs. Open Peer Review
2.3.5 Rewarding Reviewers
2.3.7 Resources and Case Studies
2.4 Sponsor Roles and Responsibilities *Updated June 2020
126.96.36.199 Publication Planning
188.8.131.52 Process Control (Content and Journal Selection)
184.108.40.206 Disclosure of Conflicts of Interest
220.127.116.11 Access to and Provision of Data
18.104.22.168 Clinical Trial Registration and Dissemination of Findings
3.0 IDENTIFICATION OF RESEARCH MISCONDUCT AND GUIDELINES FOR ACTION
3.3.1 Why Might a Manuscript be Considered Suspect?
3.3.2 Who Might Notify a Journal about a Suspect Manuscript?
3.3.3 What Should be Done When Misconduct is Alleged?
3.3.4 Whom Should a Journal Notify about a Suspect Manuscript?
3.3.5 What to do if the Submitting Author’s Response is not Satisfactory
3.3.6 Who Investigates Allegations of Misconduct?
3.3.7 What Information Should be Provided During Investigations?
3.3.8 Handling Accusations from Anonymous Sources